0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call [Seeking Alpha]

Mirum Pharmaceuticals, Inc. - common stock (MIRM)  More Company Research Source: Seeking Alpha
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
Mirum markets three drugs: LIVMARLI, Cholbam, and Chenodal, with LIVMARLI showing significant growth in treating cholestatic pruritus in ALGS and PFIC. Mirum's 2024 net product sales reached $336.4m, an 88% year-on-year increase, driven by LIVMARLI and the newly acquired bile acid medicines. The likely approval of another IBAT inhibitor, Volixibat in 2027 in PSC / PBC opens up a $500m peak annual revenue market, in my view. The other pipeline asset, MRM-3379, feels more like a "moonshot," but overall, with regard to the investment opportunity for Mirum, I believe the positives outweigh the negatives. Investment Overview Back in October last year in a note for Seeking Alpha I gave Mirum Pharmaceuticals, Inc. NASDAQ: MIRM ) stock a "Sell" rating, however, nearly six months on, the Foster City, California-based biotech's share price has risen by If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and H [Read more]
IMPACT SNAPSHOT EVENT TIME: MIRM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
MIRM alerts
from News Quantified
MIRM
NEWS
MIRM
Earnings
MIRM
Analyst Actions
MIRM
SEC Filings
Stockreport

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call [Seeking Alpha]

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
More Company Research Source: Seeking Alpha
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
Mirum markets three drugs: LIVMARLI, Cholbam, and Chenodal, with LIVMARLI showing significant growth in treating cholestatic pruritus in ALGS and PFIC. Mirum's 2024 net product sales reached $336.4m, an 88% year-on-year increase, driven by LIVMARLI and the newly acquired bile acid medicines. The likely approval of another IBAT inhibitor, Volixibat in 2027 in PSC / PBC opens up a $500m peak annual revenue market, in my view. The other pipeline asset, MRM-3379, feels more like a "moonshot," but overall, with regard to the investment opportunity for Mirum, I believe the positives outweigh the negatives. Investment Overview Back in October last year in a note for Seeking Alpha I gave Mirum Pharmaceuticals, Inc. NASDAQ: MIRM ) stock a "Sell" rating, however, nearly six months on, the Foster City, California-based biotech's share price has risen by If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and H [Read more]
IMPACT SNAPSHOT
EVENT TIME:
MIRM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS